Urolesan was used in the treatment of patients with chronic ischemic heart disease. It was established that urolesan favours improvement of the state of the vascular component of microcirculation, aggregation of erythrocytes, increase of the peripheral circulation, normalization of the blood coagulation system, optimization of external respiration, normalization of the activity of serum aminotransferases. These changes were particularly pronounced in exertion stenocardia.